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The chaperone protein Unc-93 homolog B1 (UNC93B1) regulates internalization,
trafficking, and stabilization of nucleic acid-sensing Toll-like receptors (TLR) in peripheral
immune cells. We sought to determine UNC93B1 expression and its functional relevance
in inflammatory and injurious processes in the central nervous system (CNS). We found
that UNC93B1 is expressed in various CNS cells including microglia, astrocytes,
oligodendrocytes, and neurons, as assessed by PCR, immunocyto-/histochemistry,
and flow cytometry. UNC93B1 expression in the murine brain increased during
development. Exposure to the microRNA let-7b, a recently discovered endogenous
TLR7 activator, but also to TLR3 and TLR4 agonists, led to increased UNC93B1
expression in microglia and neurons. Microglial activation by extracellular let-7b
required functional UNC93B1, as assessed by TNF ELISA. Neuronal injury induced by
extracellular let-7b was dependent on UNC93B1, as UNC93B1-deficient neurons were
unaffected by the microRNA’s neurotoxicity in vitro. Intrathecal application of let-7b
triggered neurodegeneration in wild-type mice, whereas mice deficient for UNC93B1
were protected against injurious effects on neurons and axons. In summary, our data
demonstrate broad UNC93B1 expression in the murine brain and establish this
chaperone as a modulator of neuroinflammation and neuronal injury triggered by
extracellular microRNA and subsequent induction of TLR signaling.
Keywords: UNC93B1, microRNA, let-7b, toll-like receptor, neurodegeneration, neuroinflammation,
neurons, microgliaorg September 2021 | Volume 12 | Article 7157741
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Toll-like receptors (TLRs) are pattern recognition receptors that
mediate innate immune cell signaling in response to both
pathogen- and host-derived molecules (1). A subset of
endosomal TLRs including TLR3, TLR7, TLR8, and TLR9
recognizes nucleic acids (NA), including double-stranded
RNA, single-stranded RNA, and DNA (2–4). In addition,
TLR7 was recently discovered to detect extracellular
microRNA (miRNA), such as let-7 (5, 6). UNC93B1 is an
endoplasmic reticulum (ER)-resident transmembrane protein
that controls TLR trafficking from the ER in peripheral
immune cells, such as bone-marrow-derived macrophages and
dendritic cells (7, 8). In particular, this chaperone binds to TLR3,
TLR7, and TLR9 in the ER and traffics with them to their
appropriate intracellular locations where they are subsequently
available to sense their cognate ligands (9, 10). TLR trafficking
and localization has emerged as a primary mechanism to
facilitate self versus non-self discrimination, as well as being
crucial for distinct signal transduction in peripheral immune
cells. Additionally, UNC93B1 stabilizes TLR proteins and
prevents their degradation, functions that are independent of
its endosomal trafficking activity (11). However, requirement of
UNC93B1 is not restricted to NA-sensing endosomal TLRs, as it
is also key to cell-surface expression of the flagellin-sensing TLR5
(12). Other TLRs such as TLR2 and TLR4 are assumed to act
independently of UNC93B1 (7, 12). The importance of
UNC93B1 in NA recognition and host defense is emphasized
by the development of Herpes simplex virus type 1 encephalitis
in human patients lacking functional UNC93B1 (13).
Distinct TLRs, expressed in neurons and microglia, the major
immune-competent cells in the brain, can elicit central nervous
system (CNS) damage (5, 14). In particular, activation of TLR
signaling through extracellular microRNA (miRNA) contributes
to neuroinflammation and neurodegeneration (5, 15, 16).
MiRNAs are ~22-nucleotide noncoding RNAs that, in their
conventional form, bind predominantly to the 3′-untranslated
regions of mRNAs and regulate their expression at the post-
transcriptional level (17). However, a novel role for miRNAs as
extracellular signaling molecules has been identified recently, as
they can act as endogenous TLR ligands, thereby inducing
signaling (5, 18, 19). The highly conserved let-7b, one of the
most abundant miRNAs in the human brain (20, 21), is released
from dying CNS cells and triggers neuroinflammation and
neurodegeneration through direct activation of TLR7 (5, 6).
Here, we sought to systematically analyze the expression,
regulation, and function of UNC93B1 in the brain in the setting
of TLR-mediated neuroinflammation and CNS injury induced
by extracellular let-7b. We detected the chaperone in various
CNS cell populations including neurons and glial cells.
Furthermore, UNC93B1 expression in the murine brain
increased during development. In neurons and microglia,
expression of UNC93B1 was regulated through activation of
distinct TLRs, including TLR3, TLR4, and TLR7. Both microglial
cytokine release and neuronal injury induced by extracellular let-
7b required UNC93B1 expression in vitro . Likewise,
neurodegeneration in the murine cerebral cortex in response toFrontiers in Immunology | www.frontiersin.org 2intrathecal let-7b was dependent on functional UNC93B1. Thus,
our data implicate a contribution of UNC93B1 to CNS injury
triggered by extracellular miRNA through TLR signaling.MATERIALS AND METHODS
Mice and Cell Lines
C57BL/6 (wild-type, WT) mice were purchased from Charles
River, Sulzbach, Germany. Unc93b1-/- mice were bred and
maintained under specific-pathogen-free conditions at the
animal facility of the Helmholtz Centre for Infection Research
Braunschweig, Germany, and are described in (22). Animals
were maintained and handled in accordance with the guidelines
of the committee for animal care, the German Animal Protection
Law, and approved by the Regional Office for Health and Social
Services in Berlin (Landesamt für Gesundheit und Soziales –
LAGeSo, Berlin, Germany).
N1E-115 cells, SH-SY5Y cells, and HMC3 cells were
purchased from American Type Culture Collection (Manassas,
VA, USA) and maintained in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% heat-inactivated
fetal calf serum (FCS, vol/vol) and 1% penicillin/streptomycin.
The oligodendroglial precursor cell line Oli-neu was generously
provided by Dr. J. Trotter [Institute of Molecular Biology,
Johannes Gutenberg-University, Mainz, Germany (23)] and
was cultured in DMEM supplemented with 10% fetal bovine
serum (FBS) and penicillin/streptomycin (all obtained from
Invitrogen, Darmstadt, Germany). Cells were grown at 37°C in
humidified air with 5% CO2.
Primary Cell Cultures of Microglia,
Astrocytes, and Neurons
Neonatal primary microglia were isolated from cerebral cortex and
midbrain of newborn male and female postnatal (P) 0-3 C57BL/6
and Unc93b1-/- mice, as described previously (14, 24). In brief,
forebrain was freed of blood vessels and meninges. Cortical tissue
was trypsinized for 2 min, dissociated with a fire-polished pipette,
and washed twice. Mixed glial cells were cultured for 9-12 d in
DMEM (Invitrogen, Darmstadt, Germany) supplemented with
10% FCS and 1% penicillin/streptomycin (Gibco, New York,
USA), with medium changes every third day. Microglial cells
were separated from the underlying astrocytic layer by gentle
shaking of the flasks for 1 h at 37°C on a shaker at 100 rpm.
Subsequently, microglia were plated. Resulting cell cultures usually
contained >95% microglia, as detected by isolectin b4 (IB4)
staining (for details see below). Cells were maintained at 37°C in
5% CO2 humidified atmosphere.
Cultures of enriched cortical neurons were generated from
forebrains of embryonic (E) 17 mice, as described previously
(14). In brief, brains were separated from blood vessels,
meninges, and cerebellum. Cortical tissue was treated with 500
µl of 2.5% Trypsin (Gibco, New York, USA) for 20 min at 37°C.
Trypsin activity was stopped by FBS (Invitrogen, Darmstadt,
Germany). Thereafter, cells were washed and incubated with 100
µl DNase (1 mg/ml; Roche Diagnostics, Mannheim, Germany)
for 1 min. Subsequently, cells were washed, centrifuged, andSeptember 2021 | Volume 12 | Article 715774
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glass coverslips with Neurobasal Medium (Gibco, New York,
USA) supplemented with 1% L-Glutamin, 1% penicillin/
streptomycin and 2% B27 supplement (all obtained from
Gibco, New York, USA). On the following day, half of media
was replaced, and cells were incubated for additional 48 h before
starting experiments.
Primary astrocytes were isolated, as previously described (25).
In detail, mixed glial cultures were prepared from mouse brains,
as described above (see neonatal primary microglia). After
separation of microglial cells from the underlying astrocytic
layer by gentle shaking of the flasks for 1 h at 37°C on a
shaker (100 rpm), astrocytes were trypsinized (2.5%) and
subsequently plated.
For microglia/neuron co-culture experiments half of the
medium of cultured enriched neurons was replaced by 60,000
microglia in DMEM at day 3 after plating. On the following day,
cell cultures were used for experiments.
Immunocytochemistry and
Immunohistochemistry
Immunolabeling was performed as described previously (14).
The following primary antibodies were used: anti-NeuN (1:1000
in vitro, 1:500 for sections, cat. #ABN78), anti-Neurofilament
(1:1000 in vitro, 1:500 for sections, clone DA2), anti-
microtubule-associated protein 2 (MAP-2, 1:1000, clone
AP20), anti-GFAP (1:1000 in vitro, 1:500 for sections, clone
AB5541), anti-APC (1:300, OP80), anti-active caspase-3 (1:450,
clone AB3623, all obtained from Merck Millipore, Burlington,
MA, USA), anti-Iba1 (1:1000 in vitro, 1:500 for sections; cat.
#019-19741, Wako, Neuss, Germany), anti-CD11b (1:500, M1/
70, Thermofisher Scientific, cat. #14-0112-82, Waltham, MA,
USA), and anti-TLR7 (1:500; Novus Biologicals cat. #NBP2-
27332, Centennial, CO, USA. IB4 was obtained from Invitrogen,
Darmstadt, Germany. Two rabbit polyclonal antibodies raised
against murine UNC93B1 were used in this study: anti-
UNC93B1 (#Ab72123, Abcam, Cambridge, UK, used at 1:500
dilution) recognizing the C-terminal region (aa 500-550), and
anti-UNC93B1 directed against the N-terminal region (aa 1-59)
described in (10), designated anti-UNC93-C and anti-UNC93-
N, respectively. Nuclei were stained with 4’,6-diamidino-2-
phenylindole (DAPI, 1:10,000, Sigma-Aldrich, Merck KGaA,
Darmstadt, Germany). Fluorescence microscopy was
performed using an Olympus BX51 microscope (Tokyo, Japan).
Toxicity Assays
TUNEL staining of CNS cultures was conducted using the In-
Situ Cell Detection Kit, TMR Red, following the manufacturer’s
recommendations (Roche, Basel, Switzerland). TUNEL staining
of brain sections was performed using the ApopTag Fluorescein
In-Situ Apoptosis Detection Kit, following the manual’s
instructions (Merck Millipore, Darmstadt, Germany). For
toxicity studies, the indicated amounts of let-7b oligorib
onucleotide (5′-UsGsAsGsGsUsAsGsUsAsGsGsUsUsG
sUsGsUsGsGsUsU-3′, in which “s” depicts a phosphorothioate
linkage; Purimex, Grebenstein, Germany) and other reagents
were added to cell cultures for indicated durations.Frontiers in Immunology | www.frontiersin.org 3Control cultures were incubated with phosphate-buffered
saline. Lipopolysaccharide (LPS; 1 µg/ml, List Biological
Laboratories, Campbell, CA, USA) served as positive control
for microglia-mediated neuronal injury through TLR4 signaling
in microglia/neuron co-cultures. Loxoribine (1 mM, InvivoGen,
San Diego, CA, USA) was used as positive control for TLR7-
mediated effects. The mutant oligoribonucleotide (5′-UsGsAsG
sGsUsAsGsAsAsGsGsAsUsAsUsAsAsGsGsAsU-3′) serving as
negative oligoribonucleotide control was synthesized by
Purimex, Grebenstein, Germany. For each condition,
experiments were performed in duplicates. NeuN-, activated
caspase-3-, TUNEL-, and DAPI-positive cells were quantified
by analyzing 6 high power fields (at 60x magnification) per
coverslip. The viability of control cells was set to 100%. Numbers
of NeuN-positive cells observed for each condition were
compared with control condition, as indicated, and results
were expressed as relative neuronal viability.
Real-Time PCR
Total RNA was isolated from primary cultured microglia and
neurons from WT and UNC93B1-deficient mice, as well as from
Oli-neu, N1E-115, SH-SY5Y, and HMC3 cells using InviTrap
Spin Universal RNAMini Kit (Invitek GmbH, Berlin, Germany).
RNA quality and yield were determined by NanoDrop ND-1000
(Thermofisher Scientific, Waltham, MA, USA). First, strand
cDNA synthesis of RNA was performed using the Superscript
II (Invitrogen, Carlsbad, CA, USA) reverse transcriptase
according to the manufacturer’s instructions. For mRNA
transcription, oligo-dT primers (Invitrogen, Carlsbad, CA,
USA) were used. Gene amplification was conducted in
duplicates using SYBR Green PCR mix (Applied Biosystems,
Foster City, CA, USA) with the following PCR conditions: 95°C
for 10 min, 95°C for 15 sec, 60°C for 30 sec, 72°C for 15 sec for 40
cycles using the 7500 Fast Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). Sequences of primers used
were specific for the respective candidate molecule (Qiagen,
Hilden, Germany): sense 5′GTGCCCTATGCCTACATCCG-3′,
anti-sense 5′-CAGCCACCAAGAAGATGTCA-3′ (Unc93b1);
sense 5′-GCAAGCCAGAGCAGTACTGTG-3′, anti-sense 5′-G
CCTCTGTAAGAGATCAGGTAG-3′ (IRAK1); sense 5′-CCC
TGAAGTACCCCATTGAA-3′, anti-sense 5′-GTGGACA
GTGAGGCCAAGAT ’-3′ (b-actin). 5′-CATCACTGCC
ACCCAGAAGACTG-3′, anti-sense 5′-ATGCCAGTGA
GCTTCCCGTTCAG-3 ′ (Gapdh) . Changes in mouse
UNC93B1 gene expression were analyzed by the comparative 2
(–DDCt) method relative to b-actin or GAPDH gene expression
levels, as indicated.
Intrathecal Injection Into Mice
Intrathecal injection into mice was performed as described
previously (5, 26). 10 µg RNA were used for injections, and
brains were analyzed 72 h later. After transcardial perfusion
with 4% paraformaldehyde (PFA, vol/vol), brains were removed
and cryoprotected in 30% sucrose (vol/vol). Cryostat coronal
sections (15 µm) were thaw-mounted on coated glass slides.
Representative brain sections (level 1: interaural 6.60 mm; level
2: 5.34 mm; level 3: 3.94 mm; level 4: 1.86 mm; level 5: -0.08 mm)September 2021 | Volume 12 | Article 715774
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solution (5% normal goat serum) for 3 h. Sections were then
incubated with the respective primary antibody overnight at 4°C.
Subsequently, sections were incubated with the relevant secondary
antibody (all purchased from Jackson Immuno Research, West
Grove, USA) for 1 h at room temperature.
Quantification of CNS Cells in
Brain Sections
Numbers of neurons in the cerebral cortex were assessed by
quantifying NeuN-positive cells in 6 fields (at 60x magnification)
of the right and left cerebral cortex at level 4 of the 5
representative sections in each brain (see above). The mean
was calculated, which is expressed as NeuN-positive cells per
mm2. For analysis of apoptotic cells, brain sections were stained
with TUNEL assay and DAPI. TUNEL-positive nuclei were
counted in the cerebral cortex from the representative levels 1
through 5 (see above) after visual verification of apoptotic
hallmarks such as shrinkage, blebbing, and fragmentation, and




Primary cultures of microglia were generated fromC57BL/6mice as
described above. Microglia were incubated with 5 µg/ml of let-7b or
mutant oligoribonucleotide for indicated durations, or were exposed
to increasing concentrations of let-7b ormutant oligoribonucleotide,
as indicated, complexed to the transfection agent LyoVec
(InvivoGen #LYEC-RNA, San Diego, CA, USA) for 12 h.
Conditioned medium was collected and analyzed by enzyme-
linked immunosorbent assay with hamster antibody against
mouse TNF-a (BD Biosciences, Franklin Lakes, NJ, USA) as a
capture antibody and biotin-labeled antibody against mouse as
secondary antibody (BD Biosciences, Franklin Lakes, NJ, USA).
Flow Cytometry
Murine microglia, astrocytes, and neurons were isolated as
described above. After fixation and permeabilization (Cytofix/
Cytoperm Kit, BD Biosciences, Heidelberg, Germany), cells were
incubated for 30 min at 4°C with the following antibodies: anti-
CD11bPacBlue (M1/70, eFluor 450, cat. #480112-82,
Thermofisher Scientific, Waltham, MA, USA), anti-GLAST
(ACSA-1)-APC (Miltenyi Biotec, cat. #130-095-814, Bergisch
Gladbach, Germany), anti-bIII-Tubulin (clone: TUJ1, BD
Biosciences, cat. #560394, Franklin Lakes, NJ, USA), anti-
UNC93B1-N (1:500), with secondary PerCP conjugate and
their recommended isotype controls (Thermofisher Scientific,
Waltham, MA, USA). All antibodies were used at 1:100, unless
indicated otherwise. Blocking of Fcg-receptors (Thermofisher
Scientific, Waltham, MA, USA) was conducted before cell
surface and intracellular staining. Flow cytometric analysis was
performed on FACS Canto II (BD Biosciences, Heidelberg,
Germany) and analyzed by FlowJo software (TreeStar, Inc.).
UNC93B1 expression was indicated as median fluorescence
intensity and presented in histograms.Frontiers in Immunology | www.frontiersin.org 4RNA-Seq Data Extraction
The following RNA-seq datasets (available at http://www.
brainrnaseq.org) were extracted: i) RNA-seq data from various
murine embryological (E), postnatal (P), and adult microglia (27,
developmental stages indicated in Supplementary Figure 1),
ii) astrocytes, neurons, oligodendrocyte precursor cells, newly
formed oligodendrocytes, myelinating oligodendrocytes,
microglia/macrophages, and endothelial cells from the adult
mouse cerebral cortex (28), and iii) fetal astrocytes, mature
astrocytes, neurons, oligodendrocytes, microglia/macrophages,
and endothelial cells purified from the temporal lobe of juvenile,
adult or fetal human patients (29). Gene expression levels were
expressed as fragments per kilobase per million (FPKM).
Statistical Analysis
Data are expressed as mean ± SEM or ± SD, as indicated.
Statistical differences over all groups were determined by the
non-parametric Kruskal-Wallis or one-way ANOVA test, as
indicated. Statistical differences within the group and between
the groups were determined by Dunn’s multiple comparison
post-hoc test, or unpaired Student’s t-test, respectively. Statistical
differences were considered to be significant when p < 0.05.RESULTS
UNC93B1 Is Expressed in Various CNS
Cell Populations, Including Neurons
and Glial Cells
We sought to investigate UNC93B1 expression and its functional
relevance in the brain. To this end, we first analyzed different
enriched CNS cell types such as microglia, astrocytes, and neurons,
as well as whole brain tissue derived from C57BL/6 (wild-type, WT)
mice regarding Unc93b1mRNA expression by end-point PCR. For
comparison, tissue fromWT spleen, liver, and lung were included in
this experimental approach. Respective cells and tissue isolated from
Unc93b1-/- mice served as negative control. In addition, we tested
Oli-neu cells representing an oligodendrocyte precursor cell system,
and the murine neuroblastoma cell line N1E-115, the latter
exclusively containing neuron-derived cells and thus suitable to
rule out expression signals due to potentially contaminating non-
neuronal cells such as glia, for Unc93b1 expression (Figure 1A).
Unc93b1 RNA was readily detectable in WT whole brain, its
expression signal comparable to that in lung and liver tissue, but
at lower level compared to spleen tissue. Primary microglia and
astrocytes derived from WT mice showed similar Unc93b1
transcript amounts, while Oli-neu cells and primary WT neurons
also displayed a distinct, but comparatively weaker signal
(Figure 1A). PCR analysis also revealed Unc93b1 RNA expression
in N1E-115 cells, thereby validating UNC93B1 expression in
neuronal cells. In contrast to the findings on the different WT-
derived tissues and cell types described above, Unc93b1 RNA was
not detected in any cell or tissue sample derived from Unc93b1-/-
mice, confirming the specificity of the expression signals observed in
WT samples (Figure 1A). Unc93b1 RNA was readily detectable in
the human neuroblastoma cell line SH-SY5Y, while no significantSeptember 2021 | Volume 12 | Article 715774
Klammer et al. UNC93B1 in the Brainexpression was found in the human microglial cell line HMC3
(Figure 1A). Analysis of previously published RNA-Seq datasets
derived from various murine and human brain cell populations
(27–29) identified microglia as the predominant CNS cell type
expressing Unc93b1 transcripts at comparatively high levelFrontiers in Immunology | www.frontiersin.org 5(Supplementary Figure 1). Also, these data indicate a lower
Unc93b1 expression level in human microglia compared to
mouse-derived cells. However, although at significantly lower
level, all tested CNS cell populations, including neurons, were




FIGURE 1 | UNC93B1 is expressed in various CNS cell types. (A) Total RNA was extracted from purified cortical neurons, astrocytes, and microglia, as well as from
whole brain, spleen, liver, and lung, derived from C57BL/6 (wild-type, WT) and Unc93b1-/- mice. In addition, RNA from N1E-115 cells, Oli-neu cells (left panel), as
well as human-derived HMC3 and SH-SY5Y cells (right panel) was isolated. Samples were analyzed by RT-PCR, using primers for Unc93b1. b-actin served as
loading control. NTC, non-template control; RT-, condition without reverse transcriptase. (B) Purified WT cortical neurons, microglia, and astrocytes were
immunolabeled with an antibody directed against the C-terminus of UNC93B1 (anti-UNC93B1-C) and co-stained with IB4 to mark microglia, with GFAP antibody to
mark astrocytes, and with MAP-2, NeuN, and neurofilament (NF) antibodies to label neurons. Oli-neu cells were immunolabeled with the UNC93B1-C antibody and
the oligodendrocyte marker APC. Scale bar, 50 µm. (C, D) Brain sections from WT and Unc93b1-/- mice were immunolabeled using antibodies directed against
UNC93B1-C, NeuN, GFAP, and CD11b, the latter serving as markers for neurons, astrocytes, and microglia/brain macrophages, respectively. An overview (C) and
higher magnification images (D) of the cerebral cortex displaying the respective CNS cell populations are shown. Arrows indicate cells co-labeled with UNC93B1
antibody and the respective cell type marker. Scale bar, 50 µm. (E) WT brain tissue was dissociated, and cells were stained with both anti-UNC93B1-N antibody,
recognizing the N-terminal region of UNC93B1, and different surface markers, as indicated. Microglia were defined as CD11b+GLAST-, astrocytes as CD11b-
GLAST+, and neurons as CD11b-CD45-bIII-tubulin+ cells. Subsequently, cells were analyzed by flow cytometry. One representative experiment out of 3 with similar
results is shown.September 2021 | Volume 12 | Article 715774
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as described above.
Immunocytochemical analysis of WT cell cultures with an
UNC93B1 antibody revealed cytosolic UNC93B1 protein
expression in cortical neurons, microglia, and astrocytes. Also,
Oli-Neu cells displayed distinct UNC93B1 expression
(Figure 1B). Next, to analyze UNC93B1 protein expression in the
cerebral cortex, brain sections of bothWT andUnc93b1-/-mice were
immunolabeled with an UNC93B1 antibody. WT cerebral cortex
displayed widespread UNC93B1 expression (Figure 1C), and co-
immunolabeling with a NeuN antibody identified UNC93B1-
positive cells mainly as neurons (Figures 1C, D). However,
although to a much lesser extent, UNC93B1 expression was also
detected in microglia and astrocytes, as assessed by immunolabeling
with CD11b and glial fibrillary acidic protein (GFAP) antibodies,
respectively (Figure 1D). The specificity of the UNC93B1 antibody
used for immunohistochemistry was confirmed by labeling brain
sections derived from Unc93b1-/- mice, in which no specific signal
was detected after exposure to the UNC93B1 antibody (Figures 1C,
D). Expression and localization of TLR7, one of the chaperone’s
client receptors, in the cerebral cortex did not significantly differ
between WT and Unc93b1-/- mice (Supplementary Figure 2).
In order to quantify UNC93B1 protein expression in cortical
neurons, microglia, and astrocytes we performed flow cytometry.
To this end, whole brain tissue from WT mice was dissociated
and labeled with different cell-specific surface markers, as well
as an UNC93B1 antibody. Microglia were defined as
CD11b+GLAST-, astrocytes as CD11b-GLAST+, and neurons as
CD11b-CD45-bIII-tubulin+ cells (Figure 1E). As indicated in the
representative dot plot, 34.2% of microglia, 14.3% of neurons,
and 34.7% of astrocytes expressed UNC93B1 (Figure 1E). The
specificity of the UNC93B1 antibody used for flow cytometry was
confirmed by analyzing Unc93b1-/- astrocytes, in which no
UNC93B1 expression was detectable (Supplementary Figure 3).
In summary, our expression studies revealed constitutive
UNC93B1 expression in various CNS cell populations, including
microglia, as well as neurons, astrocytes, and oligodendrocytes.
UNC93B1 Expression Increases During
Brain Development
To analyze UNC93B1 expression in the developing mouse brain,
brain tissue fromC57BL/6mice at 12 different developmental stages
including E13-19, P0, postnatal days P4, P8, and P12, as well as the
age of 5 months (P5m) were analyzed by semiquantitative
(Figure 2A) and quantitative real-time (Figure 2B) PCR using
primers specific for UNC93B1. For quantitative comparison,
interleukin-1 receptor-associated kinase 1 (IRAK1), a component
of the canonical TLR downstream signaling pathway (1), was
included in this experiment. Relative quantification was assessed
using the formula 2–DCT and by normalizing the amount of the
target gene to the housekeeping gene GAPDH, whose expression
levels were not significantly altered during brain development (data
not shown). Expression of Unc93b1 mRNA in the brain steadily
increased during the different developmental stages, reaching a peak
at P12 (Figures 2A, B), whereas IRAK1 expression did not
significantly change during the whole analyzed period
(Figure 2B). In accordance with our findings on Unc93b1 mRNAFrontiers in Immunology | www.frontiersin.org 6expression in the developing brain, immunohistochemical analysis
of the WT neocortex revealed increasing UNC93B1 expression
through the different embryonic, postnatal, and adult
stages (Figure 2C).
UNC93B1 Expression in Microglia
and Neurons Is Regulated by Distinct
TLR Activators, Including Extracellular
let-7b miRNA
While microglia express all TLRs identified to date, neurons
express only a few TLRs under certain conditions (30, 31). We
sought to determine whether UNC93B1 expression in microglia
and neurons is affected by TLR activation. To this end, enriched
microglia and neurons derived from WT mice were exposed to
the TLR3 agonist poly(I:C), the TLR4 agonist LPS, the TLR7
agonist loxoribine, and to CpG ODN1668, a TLR9 agonist. Also,
cells were incubated with the oligoribonucleotide let-7b, which
was recently identified as an endogenous TLR7 activator (5, 6).
After 6 h, cells were dissociated and immunostained with an
UNC93B1 antibody and the respective cell type-specific surface
markers. Subsequently, cells were analyzed by flow cytometry
(Figure 3A), and UNC93B1 expression was quantified by
assessing median fluorescence intensity (MFI; Figure 3B). Poly
(I:C) and LPS treatment resulted in increased UNC93B1
expression in both microglia and neurons. Likewise, exposure
to extracellular let-7b led to an increase in relative UNC93B1
expression in these cells (Figures 3A, B). UNC93B1 expression
in microglia and neurons treated with loxoribine or CpG
ODN1668 was not significantly altered compared to control
(Figures 3A, B). To determine expression changes of Unc93b1
mRNA in microglia and neurons exposed to these TLR
activators, qPCR with primers against Unc93b1 was performed
(Figure 3C). Consistent with our findings on UNC93B1 protein
expression, poly(I:C) and LPS treatment resulted in a significant
increase in relative Unc93b1mRNA expression in both microglia
and neurons (microglia: poly(I:C), 3.79 ± 0.32, p = 0.001; LPS,
2.59 ± 0.51, p = 0.036; neurons: poly(I:C), 3.51 ± 0.22, p = 0.0003;
LPS 2.5 ± 0.22, p = 0.0023; Figure 3C). Likewise, let-7b miRNA
treatment induced a significant increase of relative Unc93b1mRNA
expression in both cell types (microglia: 3.54 ± 0.16, p = 0.0001;
neurons: 1.79 ± 0.22, p = 0.0215; Figure 3C). Exposure to loxoribine
and CpG ODN1668 had no effect on Unc93b1 transcript levels,
neither in microglia nor in neurons (microglia: loxoribine, 1.28 ±
0.39, p = 0.5154; CpG ODN1668, 1.46 ± 0.24, p = 0.131; neurons:
loxoribine, 1.15 ± 0.17, p = 0.4331; CpG ODN1668, 1.17 ± 0.26, p =
0.5444; Figure 3C).
Taken together, let-7b, poly(I:C), and LPS, established TLR7,
TLR3, and TLR4 activators, respectively, induced UNC93B1
expression in microglia and neurons.
UNC93B1 Is Required for let-7b-Induced
Neuroinflammation And Neuronal Injury
Mediated by Microglia In Vitro
Activation of TLRs in the CNS leads to the release of cytokines
and chemokines from microglia, thereby triggering a
neuroinflammatory response and subsequent brain tissue
injury (32). In particular, TLR7 activation by extracellularSeptember 2021 | Volume 12 | Article 715774
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However, the role of UNC93B1 in this context has not been
explored yet. Thus, we analyzed supernatant from WT and
Unc93b1-/- microglia incubated with increasing doses of let-7b
after 24 h or with 5 µg/ml let-7b for various time periods by TNF-
a ELISA (Figures 4A, B). While loxoribine was used as positive
control for TLR7-induced microglial activation, LPS served as
positive control for microglial activation through TLR4. A
mutant oligoribonucleotide harboring the let-7b sequence with
reduced GU content (containing six nucleotide exchanges in the
central and 3′ regions), which does not activate TLR7 (5), served
as negative control in this experimental set-up. WT microglia
released TNF-a in response to let-7b, and this effect was dose
(Figure 4A)- and time (Figure 4B)-dependent, as expected. let-
7b-induced TNF-a release from microglia required UNC93B1,
as Unc93b1-/- microglia failed to respond to let-7b during the
entire time course (Figures 4A, B). Likewise, while loxoribine
induced TNF-a release from microglia, no such response was
detected in cell cultures containing UNC93B1-deficient
microglia (Figures 4A, B). In contrast and as expected, LPS-
induced cytokine release was not dependent on UNC93B1Frontiers in Immunology | www.frontiersin.org 7expression, as both WT and Unc93b1-/- microglia released
similar TNF-a amounts (Figures 4A, B). The control mutant
oligoribonucleotide did not induce microglial TNF-a release
during the whole time period observed, regardless of the
genotype, as expected (Figures 4A, B).
Activation of microglial TLRs, including TLR7 and TLR4, can
contribute to neuronal injury (5, 14, 15). We analyzed the role of
UNC93B1 in this context, particularly in the setting of neuronal
damage triggered by extracellular let-7b. To this end, WT neurons
co-cultured with WT microglia or Unc93b1-/- microglia were
incubated with let-7b or mutant oligoribonucleotide. LPS served
as positive control for neuronal injury through TLR4 in microglia.
Subsequently, co-cultures were immunolabeled with Iba-1
(Figure 4C) and NeuN (Figure 4D) antibodies to mark microglia
and neurons, respectively. While immunocytochemistry revealed
morphologically transformed microglia in let-7b-treated co-
cultures, indicating cellular activation and resembling those
treated with loxoribine, the morphology of Unc93b1-/- microglia
in response to let-7b treatment did not differ from that of
unstimulated microglia (Figure 4C). Exposure of both co-cultures
containing WT or Unc93b1-/- microglia to LPS led to a cell shapeA
B
C
FIGURE 2 | Expression of UNC93B1 in the mouse brain increases during development. Brain homogenates from C57BL/6 mice at various embryonic (E), postnatal
(days after birth, P), and adult (age of months, Pm) stages, as indicated, were assayed by endpoint RT-PCR (A) and quantitative real-time PCR (B) using primers for
Unc93b1 and IRAK1. Relative quantification was assessed using the formula 2–DCT and by normalizing the amount of the target gene to the housekeeping genes b-
actin (A) and GAPDH (B). The mean value of E13 was set to 1-fold induction, and mean values of all other developmental stages were related to E13 (n = 3). Results
are presented as mean ± SD. (C) Immunolabeling of the C57BL/6 cerebral cortex at different developmental stages, as indicated, with the UNC93B1-C antibody.
Scale bar, 200 µm.September 2021 | Volume 12 | Article 715774
Klammer et al. UNC93B1 in the BrainA
B
C
FIGURE 3 | UNC93B1 expression in microglia and neurons is regulated by TLR activation. (A) Microglia and neurons isolated from C57BL/6 mice, were exposed to
poly(I:C) (150 µg/ml), LPS (1 µg/ml), loxoribine (1 mM), CpG-ODN 1668 (50 µM), or let-7b oligoribonucleotide (20 µg/ml) for 6 h Subsequently, cells were dissociated,
labeled with both anti-UNC93B1-N and the respective antibodies for cell-specific markers, and were analyzed by flow cytometry. (B) Results were expressed as fold
change of UNC93B1 PerCP median fluorescence intensity of CD11b+ (microglia) and betaIII-tubulin+ (neurons) cells (relative MFI; TLR agonist treatment vs. control,
ctrl; n = 3) and are presented as mean ± SEM. (C) qPCR analysis of the cell cultures treated as described above using primers against UNC93B1 was performed.
b-actin served as loading control. Relative Unc93b1 mRNA expression levels (TLR agonist treatment vs. control, ctrl) are shown (n = 3). Results are presented
as mean ± SEM. P values for relevant groups were determined by Student’s t test. p* < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.Frontiers in Immunology | www.frontiersin.org September 2021 | Volume 12 | Article 7157748




FIGURE 4 | Neuroinflammatory response and neuronal injury in response to extracellular let-7b are dependent on UNC93B1 in vitro. Microglia derived from C57BL/
6 (wild-type, WT) and Unc93b1-/- mice were incubated with various doses of let-7b oligoribonucleotide, as indicated, for 12 h (A), or with 10 µg/ml let-7b for various
durations, as indicated (B). Mutant oligoribonucleotide (20 µg/ml, 12 h) and the transfection agent LyoVec served as negative control. LPS (100 ng/ml, 12 h) was
used as positive control for microglial TNF-a release through TLR4 activation, while loxoribine (1 mM, 12 h) served as control for TLR7-dependent TNF-a release.
Subsequently, supernatants were analyzed by TNF-a ELISA. Results are presented as mean ± SD. n = 4; n.d., not detectable. (C–E) WT neurons co-cultured with
either WT or Unc93b1-/- microglia were treated with various let-7b doses (C, D: 10 µg/ml for 72 h; E: as indicated for 5 d). Mutant oligoribonucleotide (5 µg/ml)
served as negative control, LPS (100 ng/ml) served as positive control for microglial activation, and loxoribine (10 mM) served as positive control for TLR7-dependent
microglial activation. Subsequently, co-cultures were immunolabeled with Iba1 (C) and NeuN (D) antibodies to mark microglia and neurons, respectively. Scale bar,
50 µm. (E) Quantification of NeuN-positive cells in co-cultures treated as described above. Untreated control was set to 100%. For each condition, experiments
were performed in duplicates. At least 3 independent experiments were performed. Data are expressed as mean ± SEM. Kruskal-Wallis test was used to determine
global significance over all conditions (p = 0.0406 over WT and p = 0.0897 over Unc93b1-/-). P values of relevant groups (indicated condition vs. unstimulated
control, ctrl) were determined by Dunn’s multiple comparison test. P values between the respective groups of WT vs. Unc93b1-/- (in brackets) were assessed by
unpaired Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001.Frontiers in Immunology | www.frontiersin.org September 2021 | Volume 12 | Article 7157749
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neurons in let-7b-treated co-cultures containing WT microglia
revealed a dose-dependent decrease in relative neuronal viability,
as expected (Figures 4D, E). In contrast, co-cultures containing
Unc93b1-/- microglia did not exhibit significant loss of neurons
when using let-7b doses as high as 10 µg/ml. Numbers of neurons in
these co-cultures exposed to let-7b did not significantly differ from
those in cell cultures exposed to the mutant oligonucleotide
(Student’s t-test, p = 0.1971). Loxoribine induced a reduction in
neuronal viability in co-cultures containing WT microglia, but not
in those containing UNC93B1-deficient microglia. LPS treatment of
both co-cultures containing WT or Unc93b1-/- microglia led to a
reduction in neuronal viability (Figures 4D, E).
Cell-Autonomous Neuronal Injury Induced
by Extracellular let-7b Is Dependent On
UNC93B1 In Vitro
Exposure of neurons to extracellular miRNAs can trigger cell-
autonomous injury through neuronal TLR7, independently on the
presence of microglia (5). Here, we aimed at assessing the role of
UNC93B1 in cell-autonomous neuronal apoptosis triggered by
extracellular let-7b. To this end, highly enriched cortical neurons
isolated from both WT and Unc93b1-/- mice were incubated with
various let-7b doses, as indicated, for 72 h (Figures 5A–C). In
addition, neurons were exposed to 5 µg/ml let-7b for different time
periods, as indicated (Figures 5D). Subsequently, neuronal
cultures were immunolabeled using neurofilament and NeuN
antibodies. Nuclei of naïve Unc93b1-/- neurons appeared larger,
and this enlargement even increased when neurons were exposed
to the different TLR agonists, including let-7b, as indicated. Also,
neuronal density in the Unc93b1-/- cell cultures seemed
consistently to be slightly decreased compared to WT cell
cultures (Figure 5B). We observed considerable axonal damage
(Figure 5A) and loss of whole neurons (Figure 5B) in WT cell
cultures in response to let-7b treatment, and the extent of damage
was comparable to that observed in neuronal cultures incubated
with loxoribine (Figures 5A–D). The neurotoxic effects induced
by let-7b were dose- (Figure 5C) and time- (Figure 5D)
dependent. In contrast, axonal morphology appeared unaffected
(Figure 5A), and neuronal numbers were unaltered (Figures 5B–
D) in neuronal cultures lacking UNC93B1 compared to control
condition during the whole observation period, even when let-7b
doses as high as 10 µg/ml were applied (Figures 5A–D). In line
with these results, TUNEL staining revealed a significant increase
in apoptotic cells in enrichedWT neuronal cultures exposed to let-
7b compared to control condition, while Unc93b1-/- neuronal cell
cultures did not show such an effect over the whole observation
period (Figures 5E, F). Whereas exposure to let-7b led to caspase-
3 activation inWT neurons after 3 d,Unc93b1-/- neurons were not
affected within this time period (Figures 5G, H). However,
numbers of active caspase-3-positive Unc93b1-/- cells increased
after 4 d. Still, at this time point numbers of caspase-3-positive
cells derived from WT were significantly increased compared to
those derived from Unc93b1-/- mice (Figure 5H). In contrast to
WT neurons, Unc93b1-/- neurons were not affected by loxoribine-
induced neurotoxicity (Figures 5A–H). LPS treatment did notFrontiers in Immunology | www.frontiersin.org 10induce neurotoxic effects, neither in WT nor in Unc93b1-/-
neuronal cultures (Figures 5A–H). Whereas exposure of WT
neurons co-cultured with WT microglia, but not Unc93b1-/-
microglia, to 10 µg/ml let-7b resulted in a 40.7% reduction in
relative neuronal viability (see Figure 4E), incubation of WT
cortical neurons alone, but not Unc93b1-/- neurons, with 5 µg/ml
and 10 µg/ml let-7b resulted in a 16.4% and 22.0% reduction in
relative neuronal viability, respectively (Figure 5C). These data
indicate that let-7b induces injury in enriched neurons, in
accordance with our previous studies on cell-autonomous let-7b-
induced neurodegeneration (5), and this effect increased in the
presence of microglia (relative neuronal viability: neurons, 10 µg/
ml let-7b neurons + WT microglia, vs. enriched neurons, p =
0.0101, Student’s t-test). Relevant contamination of enriched
cortical neuronal cell cultures with glia was ruled out previously
(5). Thus, we conclude that neuronal injury induced by let-7b is
cell-autonomous, but can be enhanced by microglia.
Taken together, UNC93B1 expression contributes to cell-
autonomous neuronal injury and apoptosis induced by let-7b.
UNC93B1 Is Required for let-7b-Induced
Neurodegeneration In Vivo
To explore the role of UNC93B1 in let-7b- and TLR7-mediated
neurodegeneration in vivo, WT and Unc93b1-/- mice were
intrathecally injected with let-7b oligoribonucleotide, mutant
oligoribonucleotide, or loxoribine. PBS served as negative control.
After 72 h, brains were analyzed by immunohistochemistry using
neurofilament and NeuN antibodies to mark axons and neurons,
respectively. Injection of WT mice with let-7b resulted in lesions in
the pericallosal area, and the extent of this damage was similar to that
observed in mice treated with loxoribine (Figure 6A). let-7b-induced
injury of the corpus callosum and diminished neurofilament
immunolabeling was sequence-specific, as intrathecal mutant
oligoribonucleotide did not induce such effects (Figure 6A).
Quantification of NeuN-positive cells revealed significant loss of
neurons in the cerebral cortex of WT mice treated either with let-
7b or loxoribine, but not with mutant oligoribonucleotide, as
expected. In contrast to WT mice, Unc93b1-/- mice were not
affected by let-7b- or loxoribine-induced neurotoxicity. In detail,
morphology of the corpus callosum and axons, as well as neuronal
numbers in the cerebral cortex of Unc93b1-/- mice, did not differ
between control, mutant oligoribonucleotide, loxoribine, and let-7b
conditions (Figures 6A–C). In line with these findings, TUNEL
staining of the cerebral cortex from WT mice injected with let-7b or
loxoribine showed an increase in numbers of apoptotic cells, but did
not reveal such effects in Unc93b1-/- mice (Figures 6D, E). Thus, we
conclude that functional UNC93B1 expression is crucial for let-7b-
and TLR7-triggered neurodegeneration in vivo.DISCUSSION
TLRs and associated signaling pathways contribute to both
injurious and regenerative processes in CNS diseases (33–35).
We found recently that miRNAs can serve as signals for
activation of TLRs in CNS cells, a function that is independentSeptember 2021 | Volume 12 | Article 715774






FIGURE 5 | UNC93B1 is required for let-7b-induced cell-autonomous neuronal apoptosis in vitro. (A, B) Enriched cortical neurons isolated from C57BL/6 (wild-type,
WT) and Unc93b1-/- mice were exposed to 10 µg/ml let-7b for 72 h or were left untreated (control). Mutant oligoribonucleotide (5 µg/ml) served as negative control.
LPS (100 ng/ml) was used to indicate functionally relevant microglia cell numbers in the enriched neuronal cell cultures. Loxoribine (10 mM) served as positive control
for TLR7-dependent neuronal injury. Subsequently, cells were immunolabeled using Neurofilament (A) and NeuN (B) antibodies to assess axonal damage and
neuronal viability, respectively. (C, D) Cell cultures derived from WT and Unc93b1-/- mice described above were incubated with various doses of let-7b, as indicated,
for 72 h (C) or treated with 5 µg/ml let-7b for different time periods, as indicated (D). (E–H) WT cortical neurons were incubated with let-7b (5 µg/ml) for various time
periods, as indicated, and were subsequently analyzed by (E) TUNEL assay and (G) immunostaining using active caspase-3 antibody. DAPI staining marked all
present cells. Subsequently, TUNEL-positive and caspase-3-positive cells were quantified and normalized against DAPI-positive cells (F and H, respectively). Mutant
oligoribonucleotide served as negative control, while loxoribine and LPS were used as positive control. (C–H) At least three independent experiments were
performed. Data are expressed as mean ± SEM. Kruskal-Wallis test was used to determine global significance over all conditions [(C) p = 0.0042 over WT and p =
0.9557 over Unc93b1-/-; (D) p = 0.0036 over WT and p = 0.9971 over Unc93b1-/-; (F) p < 0.0001 over WT and p = 0.3514 over Unc93b1-/-; (H) p = 0.0010 over
WT and p = 0.0036 over Unc93b1-/-]. P values of relevant groups (indicated condition vs. unstimulated control, ctrl) were determined by Dunn’s multiple comparison
test. P values between respective groups of WT vs. Unc93b1-/- (in brackets) were assessed by unpaired Student’s t test. *p < 0.05; **p < 0.01; ***p < 0.001;
****p < 0.0001. Scale bar, 50 µm.Frontiers in Immunology | www.frontiersin.org September 2021 | Volume 12 | Article 71577411
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Specifically, let-7 miRNAs are direct activators of TLR7 in both
microglia and neurons (5). Subsequent studies validated our
initial hypothesis that endogenous miRNAs, such as let-7b, are
released from injured neurons, stimulate TLR7, thereby sending
a danger signal to neighboring neurons, and cause further spread
of CNS damage, particularly in the setting of neurodegenerative
diseases (5, 15). However, the exact signaling cascades and
molecular events linking TLR7 with microglia-mediated
inflammation and neuronal apoptosis remained unresolved.
Expression and function of the TLR trafficking proteinFrontiers in Immunology | www.frontiersin.org 12UNC93B1 in the setting of human herpes encephalitis was
previously described (13). Yet, the extent and cellular pattern
of UNC93B1 expression in the brain, as well as this protein’s
mode of regulation and functional impact on brain cells was
unknown. Our data show that UNC93B1 is expressed in various
CNS cells, including neurons, microglia, astrocytes, and
oligodendrocytes. Moreover, it was required for microglial
activation and neuronal injury through distinct TLRs,
particularly for the response to extracellular let-7b miRNA, but
also loxoribine, both presenting selective TLR7 activators. These




FIGURE 6 | Neurodegeneration triggered by intrathecal let-7b and loxoribine requires UNC93B1 expression. We intrathecally injected 10 mg of let-7b, 10 mg of
mutant oligoribonucleotide, 136 µg loxoribine, or PBS (control) into C57BL/6 (WT; let-7b, n = 7; mut. oligo, n = 6; loxoribine, n = 6; PBS, n = 4) or Unc93b1-/- (let-
7b, n = 5; mut. oligo, n = 6; loxoribine n = 6; PBS, n = 4) mice. After 3 d, brain sections were immunolabeled with neurofilament (A) and NeuN (B) antibodies, and
representative images of the pericallosal area and cerebral cortex, respectively, are shown [scale bar, 200 µm in (A); 50 µm in (B)]. (C) Density of neurons in the
cerebral cortex of WT and Unc93b1-/- mice was assessed quantifying NeuN-positive cells. Brain sections described above were stained with TUNEL assay (D), and
TUNEL-positive cells in the cerebral cortex were quantified (E). (C, E) One-way ANOVA was used to determine statistical significances across all tested conditions
(C) p < 0.0001 over WT and p = 0.1232 over Unc93b1-/-; (E) p < 0.0001 over WT and p = 0.571 over Unc93b1-/-]. Unpaired Student’s t-test was used to assess
significant differences between pairs (indicated group vs. control, ctrl; WT vs. Unc93b1-/-; **p < 0.01; ***p < 0.001). Scale bar, 100 µm (overview D) and 50 µm
(inlay in D).September 2021 | Volume 12 | Article 715774
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client receptors for UNC93B1. Also, our findings are in
accordance with previous studies, in which UNC93B1
expression was required for the microglial TNF-a response to
whole bacteria and RNA (36) and for apoptosis of HEK293T
cells (37).
We observed an increase in UNC93B1 expression in the
developing mouse brain, while the expression of IRAK-1,
representing a canonical TLR signaling-associated molecule,
remained unchanged. Similar changes in mRNA expression of
specific TLR family members, especially those linked to
UNC93B1 function such as TLR3, TLR7, and TLR9, during
mouse brain development have been previously described (38).
Also, in accordance with our findings, Matcovitch-Natan and
colleagues’ previous RNA-Seq studies indicate a steady increase
in Unc93b1 expression in murine microglia during the different
brain developmental stages, reaching a peak at early postnatal
stages (39). Functions of UNC93B1 beyond TLR trafficking and
stabilization are poorly known (40), and so far, a role for this
chaperone in a developmental setting has not been discussed.
However, the findings that expression of UNC93B1 and specific
TLRs changes during different developmental stages and that
expression of other TLRs, TLR adaptors such as myeloid
differentiation primary response 88 (MyD88), and associated
downstream signaling molecules is low and unaltered at the same
time (38), points to a, yet undetermined, role of the TLR
chaperone and some TLRs in brain development. Notably,
mice lacking UNC93B1 are viable, and although their brains
have not been investigated at micro anatomic level so far, no
major impairment in CNS development resulting in
morphogenetic failures in these animals has been observed (8,
10) (data not shown). Thus, UNC93B1 may not be irreplaceable
during brain development, and further molecules involved in
TLR trafficking/stabilization and signaling may have to be
considered when discussing the pathophysiological significance
of TLR-linked chaperones in developmental processes in the
vertebrate brain. Especially in the context of neurogenesis, select
TLRs including TLR7, 8 and, 9 and associated signaling
molecules have been suggested to play a functional role in
brain development (38, 41–44). In line with this, our current
data show that UNC93B1 is widely expressed in the CNS, not
only in glial cell populations, but also in neurons. Neurons of
various brain regions, in particular neocortex and hippocampus,
express both TLR7 and TLR9, the interaction partners for
UNC93B1 (5, 38). Further research will be needed to assess the
functional impact of neuronal injury induced by miRNAs such as
let-7b through UNC93B1, as observed in our current study, on
vertebrate brain development. Also, our data indicate that
UNC93B1 expression levels vary within a given CNS cell
population, e.g. murine microglia, astrocytes, and neurons (see
Figure 1E). UNC93B1 functions beyond TLR trafficking and
stabilization are poorly known in general, even unexplored in
CNS cells. Function and regulation of UNC93B1 expression may
depend not only on the developmental stage, specific
physiological and pathological conditions, or technical aspects,
e.g. cell culturing, cell isolation procedures, potentially affectingFrontiers in Immunology | www.frontiersin.org 13one fraction within a cell population, but not the other one.
Future studies may shed light on the potentially complex
function of UNC93B1 in (individual) CNS cells. Finally,
UNC93B1 function has been demonstrated to be altered by
host and viral proteases targeting the chaperone’s N-terminus
in HEK293T cells (37). Although it is conceivable that similar
mechanisms exist in CNS cells, further investigation is required
to decipher the potentially different functions of UNC93B1 in the
vertebrate brain.
We found that UNC93B1 expression in neurons and
microglia is upregulated not only by let-7b, but also by poly(I:
C) and LPS, the established agonists for TLR3 and TLR4,
respectively. This may point to a translational regulation with
TLR7 agonists. Interaction between UNC93B1 and TLR3 in
microglia was not surprising, as endosomal TLRs interact with
UNC93B1 in immune cells such as dendritic cells and
macrophages (8). The increase in UNC93B1 expression in
response to LPS might result from activation of the TNF/
interferon response factor/AP-1 signaling cascade, which is
similar among all TLRs, subsequently leading to the
transcription of UNC93B1. A direct interaction of UNC93B1
with the cell surface-localized TLR4 was not observed so far (7, 8,
10). Surprisingly, activation of TLR9, one of the UNC93B1 client
receptors in peripheral immune cells, did not significantly
modulate UNC93B1 expression, neither in microglia nor in
neurons. Likewise, and in contrast to the observed effects of
the miRNA ligand let-7b described above, loxoribine, a
guanosine analog also known as a selective TLR7 agonist,
failed to induce UNC93B1 expression in both cell types. Thus,
regulation of UNC93B1 expression and function may be organ-
and cell type-specific, but also dependent on the specific ligand
activating the respective TLR. In turn, regulation of UNC93B1
expression may be crucial for modulating UNC93B1-dependent
TLR function in brain cells, as it is seen in peripheral immune
cells (11). In particular, elevated UNC93B1 expression was found
to stabilize NA-sensing TLRs and render them hyperactive.
Studies in models of systemic lupus erythematodes indicate
that dysregulation of UNC93B1 might contribute to
autoimmune processes by enhancing the expression of
UNC93B1-dependent TLRs (45, 46). Also, competition
between TLR7 and TLR9 for UNC93B1-mediated trafficking
seems to be important for keeping NA-sensing TLRs in control
of an inflammatory environment (47, 48). However, further
studies are needed to determine whether TLR7 and TLR9 in
microglia and neurons (5, 31) underlie such mechanisms. Also,
the molecular structures responsible for the interaction between
a given TLR and UNC93B1 in CNS cells, as they were defined as
specific acidic amino acids in the juxtamembrane region of the
receptors in peripheral immune cells (8), remain unresolved at
this stage.
As described above, NA-sensing TLRs in peripheral immune
cells depend on UNC93B1 to exit the ER (9), and similar
conditions likely exist in CNS cells, particularly in microglia,
the primary immune cells in the brain. Still, the function of
UNC93B1 in endosomal trafficking, TLR protein stabilization,
and prevention of their degradation in the different CNS cellSeptember 2021 | Volume 12 | Article 715774
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unknown. The clinical relevance of UNC93B1 expression in the
brain lies in the observation that UNC93B1 deficiency in humans
predisposes individuals to Herpes simplex virus 1 (HSV-1)
encephalitis (13, 49), a life-threatening CNS infection causing
severe neurological damage. This phenotype is suggested to
result from impaired TLR3 signaling in neurons and
oligodendrocytes (49). Consistent with this, an increased risk of
herpes encephalitis after HSV-1 infection is observed in children
with autosomal dominant mutations in TLR3, indicating that TLR3
trafficking by UNC93B1 is crucial for the control of HSV-1
infection (50). In addition, the fundamental function of
UNC93B1 in maintaining TLR protein expression might be
important in this context. The inability of let-7b and loxoribine to
induce neuronal injury in UNC93B1-deficient mice as observed in
our study might be caused, at least in part, by reduced/altered TLR
expression in these mice. However, analyzing UNC93B1-deficient
dendritic cells Brinkmann et al. had previously demonstrated that
UNC93B1 deficiency does not affect TLR7 expression (10).
Accordingly, our immunohistochemistry studies did not reveal
significant differences in TLR7 expression or localization in the
cerebral cortex between the two genotypes. We concluded that
abolished neurotoxic effects in UNC93B1-deficient mice injected
with TLR7 agonists are unlikely to result from altered TLR7
expression in these animals. However, we cannot rule out that the
observed protection against the neurotoxic effects in UNC93B1-
deficient mice injected with the TLR7 activators are due to an at
least increased resistance towards neurotoxicity in general, i.e.
alteration of non-TLR-specific apoptotic signaling pathways, in
these mice. Future studies are required to shed light on these
issues and may clarify whether TLRs and their interaction with
UNC93B1 in different CNS cell populations are involved in the
pathogenesis of herpes encephalitis and/or other infectious, but also
non-infectious, CNS disorders associated with neuronal injury.
In summary, UNC93B1 is broadly expressed in the CNS. Our
findings support a role for UNC93B1 in CNS development,
inflammation, and injury, particularly triggered by extracellular
miRNAs such as let-7b, which can serve as endogenous TLR7
activators. The determinants of UNC93B1 specificity for TLRs in
CNS cells, as well as the molecular mechanisms by which
UNC93B1 potentially mediates differential trafficking pathways
and protein stabilization in the different cell types remain to be
elucidated in future studies. These lines of research may not only
contribute to our understanding of basic cell biological processes
in brain cells, but may also provide deeper insight into the
molecular mechanisms underlying various CNS diseases.
Although efforts are underway to develop TLR inhibitors to
treat brain disorders, especially autoimmune CNS diseases, thoseFrontiers in Immunology | www.frontiersin.org 14have primarily focused on the inhibition of ligand binding so far.
Deciphering the pathways controlling TLR trafficking and
localization in the brain, such as the ones involving UNC93B1,
may lead to the development of novel therapeutic strategies.DATA AVAILABILITY STATEMENT
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